FIELD: medicine.
SUBSTANCE: invention relates to new compounds of formula (I), pharmaceutical compositions made on their basis, the use and method of treating a condition or disorder mediated by CMO.
EFFECT: new compounds that are CMO inhibitors and may be useful for the treatment of disorders mediated by CMO like acute pancreatitis, chronic kidney disease, other conditions associated with systemic inflammatory response syndrome (SIRS), Huntington's disease, Alzheimer's disease, spinocerebral ataxia, Parkinson's disease , AIDS dementia complex, HIV infection, amyotrophic lateral sclerosis (ALS), depression, schizophrenia, sepsis, cardiogenic shock, severe trauma, acute lung injury, acute respiratory distress syndrome, acute cholecystitis, severe burns, pneumonia, major surgical interventions, ischemic bowel disease, severe acute liver disease, severe acute hepatic encephalopathy, or acute renal failure.
14 cl, 30 ex
Title | Year | Author | Number |
---|---|---|---|
DERIVATIVES OF 3-(5-CHLORO-2-OXOBENZO[D]OXAZOL-3(2H)-YL)PROPANOIC ACID AS KMO INHIBITORS | 2014 |
|
RU2693016C1 |
COMPOUNDS AND METHODS FOR USING | 2009 |
|
RU2561109C2 |
BENZOXAZINE-OXAZOLIDINONE COMPOUND DISPLACED BY A NITROGEN-CONTAINING HETEROCYCLE, METHOD OF SYNTHESIS AND APPLICATION THEREOF | 2018 |
|
RU2744784C1 |
ANTIBIOTIC DERIVATIVES OF 2-OXO-OXAZOLIDINE-3, 5-DIYL | 2012 |
|
RU2616609C2 |
CONDENSED BENZAMIDE DERIVATIVE AND INHIBITOR OF VANILLOID RECEPTOR TYPE 1 ACTIVITY (VRI) | 2005 |
|
RU2392278C2 |
METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTIONS | 2012 |
|
RU2665021C2 |
METHODS FOR TREATMENT OR PREVENTION OF AUTOIMMUNE DISEASES WITH USE OF 2,4-PYRIMIDINEDIAMINE | 2013 |
|
RU2659777C2 |
N- (PHENYLSULPHONYL) BENZAMIDES AND RELATED COMPOUNDS AS BCL-2 INHIBITORS | 2017 |
|
RU2744358C2 |
MDM2 PROTEIN DESTRUCTORS | 2017 |
|
RU2743432C2 |
N-(PHENYLSULFONYL)BENZAMIDES AND RELATED COMPOUNDS AS BCL-2 INHIBITORS | 2017 |
|
RU2722560C1 |
Authors
Dates
2021-04-05—Published
2016-05-19—Filed